Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 6/20 | 0.53 |
| ▸ | RAF1 | P04049 | 11/20 | 0.50 |
| ▸ | BRAF | P15056 | 11/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL182924 | 0.88 | PIK3CD (0.62) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL182735 | 0.87 | PIK3CD (0.64) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL183019 | 0.87 | PIK3CD (0.64) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL182734 | 0.81 | PIK3CA (0.62) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL6182448 | 0.80 | KIT (0.78) | KITPIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL182889 | 0.80 | PIK3CD (0.67) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL183092 | 0.79 | CLK4 (0.55) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL182771 | 0.78 | PIK3CD (0.73) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL182635 | 0.78 | PIK3CD (0.62) | KITRAF1BRAFPIK3CDPIK3CA | |
| SCHEMBL13906291 | 0.78 | CYP17A1 (0.55) | PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| EP-2049502-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2009-04-22 | — | — | EP | claimed |
| WO-2008012326-A1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | KIT 317/4885RAF1 98/4885BRAF 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.